Abstract Details

Title Diagnosed and Drug-Treated Prevalence of Essential Tremor in Pediatric Patients: Retrospective Analyses of Two US Healthcare Claims Databases

Topic Movement Disorders

Presentation(s) S51 - Movement Disorders: Tremor, Parkinsonism, and Non-motor Symptoms (3:54 PM-4:06 PM)

Poster/Presentation
Number 003

Background Pediatric ET diagnosis may represent early-onset familial ET and is predominantly diagnosed through tertiary centers. The prevalence of pediatric ET is not well-understood.

Objective To estimate the prevalence of diagnosed and drug-treated pediatric essential tremor (ET) using two US healthcare claims databases.

Design/Methods A retrospective cohort study used the Merative™ MarketScan^® Research Databases (MarketScan^®) and Symphony Integrated Dataverse (IDV^®) (01/01/2016–12/31/2019) to estimate the number of US children (age <18 years) with ET. ET diagnosis was defined as ≥2 medical claims containing ICD-10-CM code G25.0 ≥1 and ≤365 days apart. Patients with drug-treated ET were defined as those with ≥180 days of observability following ET diagnosis who subsequently received any ET medication in 2019. Age-adjusted prevalence was used to estimate the number of US children with diagnosed and drug-treated ET.

Results Estimated age-adjusted numbers (95% CIs) of US children diagnosed with ET were 8362 (7626–9230) and 6281 (5923–6629) using MarketScan and IDV, respectively. Less than half of those diagnosed with ET received pharmacological treatment for ET. Specifically, the estimated proportions (95% CIs) of pediatric patients with drug-treated ET were 33.7% (28.7%–38.7%) and 38.1% (34.8%–41.3%), respectively. Estimated age-adjusted numbers (95% CIs) of pediatric patients with drug-treated ET were 2749 (2299–3238) and 2409 (2186–2655), respectively. Beta-blockers (57% and 55%, respectively) and anticonvulsants (36% and 44%, respectively) were the most common drug classes prescribed among treated patients. The most frequently prescribed beta-blocker and anticonvulsant were propranolol (55% and 52%, respectively) and topiramate (15% and 17%, respectively).

Conclusions To our knowledge, this is the first study to estimate the US prevalence of pediatric ET using large claims databases. Pediatric ET appears rare and, concordant with the literature, less common in children than in adults. Observed low drug-treatment rates are consistent with the slow, progressive nature of ET.

Authors/Disclosures
Michelle Baladi, PhD (Jazz Pharmaceuticals) PRESENTER	Dr. Baladi has stock in Jazz Pharmaceuticals .
Ragy Saad (Jazz Pharmaceuticals)	No disclosure on file
Michael Markowitz, MD	Dr. Markowitz has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Markowitz has stock in Jazz Pharmaceuticals, UCB Pharmaceuticals, J&J.
	No disclosure on file
Douglas S. Fuller (Jazz Pharmaceuticals)	Mr. Fuller has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Fuller has stock in Jazz Pharmaceuticals.
Weiyi Ni	No disclosure on file
Rajesh Pahwa, MD, FAAN (University of Kansas Medical Center)	Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbott. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Pahwa has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for ACADIA. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amneal. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kyowa. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allevion. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Insightec. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jaaz. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuroderm. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Photopharmics. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fasikl. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sun Biopharma. The institution of Dr. Pahwa has received research support from Abbott. The institution of Dr. Pahwa has received research support from Abbvie. The institution of Dr. Pahwa has received research support from Biogen. The institution of Dr. Pahwa has received research support from Biohaven. The institution of Dr. Pahwa has received research support from EIP. The institution of Dr. Pahwa has received research support from Amneal. The institution of Dr. Pahwa has received research support from Parkinson Foundation. The institution of Dr. Pahwa has received research support from Roche. The institution of Dr. Pahwa has received research support from Sage. The institution of Dr. Pahwa has received research support from Sun Pharma. The institution of Dr. Pahwa has received research support from Theranexus. The institution of Dr. Pahwa has received research support from Theravance. The institution of Dr. Pahwa has received research support from Voyager. The institution of Dr. Pahwa has received research support from Neuroderm. The institution of Dr. Pahwa has received research support from Annovis. The institution of Dr. Pahwa has received research support from Ask Bio. The institution of Dr. Pahwa has received research support from Blue Rock. The institution of Dr. Pahwa has received research support from Cerevance. The institution of Dr. Pahwa has received research support from Fasikl. The institution of Dr. Pahwa has received research support from Praxis. The institution of Dr. Pahwa has received research support from Scion. The institution of Dr. Pahwa has received research support from UCB.
Kelly E. Lyons, PhD (University of Kansas Medical Center)	Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Dr. Lyons has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Parkinson's Foundation. Dr. Lyons has a non-compensated relationship as a President with International Essential Tremor Foundation that is relevant to AAN interests or activities.
Junji Lin, PhD (Jazz Pharmaceuticals)	Ms. Lin has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Ms. Lin has stock in Jazz Pharmaceuticals.